Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 14, 2008, Pages 4199-4203

  Shah, Unmesh ^a   Boyle, Craig D ^a   Chackalamannil, Samuel ^a   Neustadt, Bernard R ^a   Lindo, Neil ^a   Greenlee, William J ^a   Foster, Carolyn ^a   Arik, Leyla ^a   Zhai, Ying ^a   Ng, Kwokei ^a   Wang, Shiyong ^a   Monopoli, Angela ^a   Lachowicz, Jean E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

A2A; A2A antagonist; A2A receptor; A2A receptor antagonist; Adenosine; Parkinson's Disease; SCH 58261

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE DERIVATIVE; ADENOSINE A2A RECEPTOR ANTAGONIST; SCH 85261;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; IN VITRO STUDY; NONHUMAN; PARKINSON DISEASE; RAT; RECEPTOR AFFINITY;

ADMINISTRATION, ORAL; ANIMALS; BEHAVIOR, ANIMAL; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; MODELS, CHEMICAL; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PIPERAZINES; PYRIMIDINES; QUINOLINES; RATS; RECEPTOR, ADENOSINE A2A; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

RATTUS;

EID: 47149111966     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.05.074     Document Type: Article

References (21)

1. Fredholm B.B., Abbracchio M.P., Burnstock G., Daly J.W., Harden T.K., Jacobson K.A., Leff P., and Williams M. Pharmacol. Rev. 46 (1994) 143
2. Augood S.J., and Emson P.C. Mol. Brain Res. 22 (1994) 204
3. Ferre S., von Euler G., Johansson B., Fredholm B.B., and Fuxe K. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 7238
4. 2A Receptors in Parkinson's Disease and Other CNS Disorders.
5. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., and Chase T.N. Neurology 61 (2003) 293
6. Zocchi C., Ongini E., Conti A., Monopoli A., Negretti A., Baraldi P.G., and Dionisotti S. J. Pharmacol. Exp. Ther. 276 (1996) 398
7. Baraldi P.G., Cacciari B., Spalluto G., Pineda de Villatoro M.J., Zocchi C., Dionisotti S., and Ongini E. J. Med. Chem. 39 (1996) 1164
8. 1 is necessary to avoid cardiac side effects.
9. Hauser R.A., Hubble J.P., and Truong D.D. Neurology 61 (2003) 297
10. Francis J.E., Cash W.D., Psychoyos S., Ghai G., Wenk P., Friedmann R.C., Atkins C., Warren V., Furness P., Hyun J.L., Stone G.A., Desai M., and Williams M. J. Med. Chem. 31 (1988) 1014
11. Sarges R., Howard H.R., Browne R.G., Lebel L.A., Seymour P.A., and Koe B.K. J. Med. Chem. 33 (1990) 2240
12. Also see Ref. 4.
13. Ongini E. Drug Dev. Res. 42 (1997) 63
14. Neustadt B.R., Hao J., Lindo N., Greenlee W.J., Stamford A.W., Tulshian D., Ongini E., Hunter J., Monopoli A., Bertorelli R., Foster C., Arik L., Lachowicz J., Ng K., and Feng K.-I. Bioorg. Med. Chem. Lett. 17 (2007) 1376
15. All of the final compounds in this publication were synthesized by the mesylate alkylation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine 4 shown in Scheme 1. A mixture of 7- and 8-alkylated products was formed. The N-8 alkylated analogs were generally inactive.
16. 2A receptors did not differ from affinity for the human receptor
17. Procedure described in:. Cox K.A., Dunn-Meynell K., Korfmacher W.A., Broske L., Nomeir A.A., Lin C.-C., Cayen M.N., and Barr W.H. Drug Discov. Today 4 (1999) 232 %CV values typically range from 10 to 30 in this assay (n = 2)
18. Inhibition of haloperidol-induced catalepsy is an in vivo assay used to evaluate Parkinson's drugs (>30% inhibition is considered to be active in this assay).
19. Mandhane S.N., Chopde C.T., and Ghosh A.K. Eur. J. Pharmacol. 328 (1997) 135
20. Procedure described in. Matasi J.J., Caldwell J.P., Zhang H., Fawzi A., Cohen-Williams M.E., Varty G.B., and Tulshian D.B. Bioorg. Med. Chem. Lett. 15 (2005) 3670
21. The nephelometric (light scattering) method was used to determine the kinetic solubility of compounds. The test compound (1.0 mg) was dissolved in DMSO at 25 mM. A serial dilution into DMSO was performed and 3 μl of the compound in DMSO at various concentrations was added to the buffer (10 mM phosphate, pH 7.4). Presence of precipitate was detected by nephelometry. Solubility was defined as the highest concentration of material that did not scatter light. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Deliv. Rev. 46 (2001) 3